BRVE
Braveheart Bio, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-23/100
Last price
19.79
▼ 1.56 (7.31%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
21.35
Day high
21.59
Day low
19.68
Volume
590.32K
Market cap
$1.78B
P/E (TTM)
—
52W range
19.67 – 32.00
Trailing performance
Returnvs SPY
1W
-11.41%
-13.4%
1M
-25.99%
-27.1%
3M
—
-4.5%
6M
—
-18.2%
YTD
-33.59%
-47.8%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BRVE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
47.47M
Total on file
Fundamentals
Market cap$1.78B
Enterprise value$1.71B
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-98.45M
EPS (TTM)$-6.08
Free cash flow—
Total cash$122.83M
Total debt$575.00K
Book value / share$-11.48
Shares outstanding90.04M
Float13.40M
Short % of float—
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-9.94
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity0.49
Current ratio13.63
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | YoY |
|---|---|---|
| Basic EPS | -5.32 | |
| Diluted EPS | -5.32 | |
| Basic shares | 12.41M | |
| Diluted shares | 12.41M |
| Line item | 2025 | YoY |
|---|---|---|
| Shares issued | 73.15M |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | — | $0 | — | — |
| Operating revenue | $0 | — | $0 | — | — |
| Research & development | $11.13M | — | $0 | — | — |
| Selling, general & admin | $4.76M | — | $27.00K | — | — |
| Total operating expense | $15.88M | — | $27.00K | — | — |
| Operating income | -$15.88M | — | -$27.00K | — | — |
| Net interest income | $889.00K | — | $0 | — | — |
| Pre-tax income | -$14.99M | — | -$381.00K | — | — |
| Net income | -$14.99M | — | -$381.00K | — | — |
| Net income to common | -$18.60M | — | -$381.00K | — | — |
| Basic EPS | -0.25 | -0.33 | -0.01 | -0.00 | +22.9% |
| Diluted EPS | -0.25 | -0.33 | -0.01 | -0.00 | +22.9% |
| EBIT | -$15.88M | — | -$27.00K | — | — |
| EBITDA | -$15.88M | — | -$27.00K | — | — |
| Basic shares | 73.15M | 42.82M | 42.82M | 42.82M | +70.8% |
| Diluted shares | 73.15M | 42.82M | 42.82M | 42.82M | +70.8% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $122.83M | — | — |
| Cash & short-term investments | $122.83M | — | — |
| Total current assets | $123.44M | — | — |
| Property, plant & equipment | $630.00K | — | — |
| Total assets | $126.96M | — | — |
| Total current liabilities | $9.06M | — | — |
| Total debt | $575.00K | — | — |
| Total liabilities | $222.86M | — | — |
| Retained earnings | -$95.91M | — | — |
| Shareholder equity | -$95.91M | — | — |
| Working capital | $114.39M | — | — |
| Net tangible assets | -$95.91M | — | — |
| Shares issued | 73.15M | 73.15M | 0.0% |
| Line item | 2026-06-30 | 2025-06-30 | YoY |
|---|---|---|---|
| Net income | -$14.99M | -$381.00K | -3,833.9% |
| Depreciation & amortisation | $3.00K | $0 | — |
| Stock-based compensation | $1.09M | $0 | — |
| Change in working capital | -$3.05M | $27.00K | -11,407.4% |
| Operating cash flow | -$16.95M | $0 | — |
| Investing cash flow | $8.00K | $0 | — |
| Financing cash flow | $59.20M | $2.00K | +2,959,750.0% |
| Free cash flow | -$16.94M | $0 | — |
| End cash position | $122.83M | $2.00K | +6,141,450.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.69 | -2.51 | -193.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.44 | 5 | $0 | — |
| Next quarter | -0.29 | 5 | $0 | — |
| Current year | -1.47 | 5 | $0 | — |
| Next year | -1.62 | 5 | $0 | 0.0% |
Analyst targets & ownership
Mean target$45.25
High target$48.00
Low target$40.00
Implied upside128.65%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders58.16%
Held by institutions23.64%
Institutions holding14
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
21.29
-7.04% from price
SMA 20
24.12
-17.95% from price
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
22.12
-10.52% from price
EMA 26
23.89
-17.17% from price
EMA 50
—
—
RSI (14)
35.8
Neutral
MACD (12,26,9)
-1.78
Hist -0.36
ATR (14)
2.40
12.10% of price
Realised vol 30D
93.6%
Annualised
Bollinger upper
30.36
20, 2σ
Bollinger lower
17.88
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
93.6%
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
-34.0%
Peak to trough
Max drawdown 5Y
-34.0%
Peak to trough
ATR 14
2.40
12.10% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
2.46M
Prior 847.77K
Change vs prior
+190.3%
Shorts adding
% of float
—
—
% of shares out
2.73%
Against total outstanding
Days to cover
8.5
Crowded exit
Float
13.40M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-07
Offering Registrations
S-8 · 2026-08-06
Offering Registrations
S-1MEF · 2026-08-05
Trading Registrations
8-A12B · 2026-08-03
Offering Registrations
S-1/A · 2026-07-30
Offering Registrations
S-1 · 2026-07-15
Offering Registrations
DRS/A · 2026-06-08
Headlines
Braveheart Bio to Participate in Stifel Cardiometabolic Forum
GlobeNewswire · 21d ago
Braveheart Bio Q2 Net Loss Widens
MT Newswires · 29d ago
Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 29d ago
The Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’
TipRanks · 29d ago
Braveheart Bio to Participate in Cantor Global Healthcare Conference
GlobeNewswire · 36d ago
Insiders Are Betting Big on These 3 Healthcare Stocks
MarketBeat · 37d ago
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
The Fly · 37d ago
Jefferies starts biopharma firm Braveheart at Buy after IPO
Investing.com · 37d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.